Yann LeCun, the former chief AI scientist at Meta, has announced that his new company, Advanced Machine Intelligence (AMI), has successfully raised $1 billion to further its development of innovative “world models.” This significant funding is poised to benefit Nabla, an AI documentation company that is already collaborating closely with AMI. The announcement comes during the ongoing health tech conference HIMSS, bringing attention to the intersection of artificial intelligence and healthcare.
Nabla stands to gain early access to the advanced technologies being developed at AMI, which aims to enhance automation in healthcare settings. Alex LeBrun, the co-founder and CEO of Nabla, leads this initiative, with Yann LeCun himself as one of Nabla’s investors. Although there is no formal equity or licensing agreement between the two companies yet, they are actively working together to explore the potential of AMI’s technology.
In a recent blog post, LeBrun, along with Nabla’s Chief Operating Officer Delphine Groll and Chief Technology Officer Martin Raison, outlined their vision for how world models can transform healthcare. These models are designed to “learn abstract representations of how environments function,” allowing for a reasoning process more akin to human cognition. The executives emphasize that this approach could lead to safer and more predictable outcomes compared to current probabilistic language models. They contend that AMI’s technology could offer “safe, deterministic, auditable decision-making,” paving the way for credible regulatory pathways for autonomous systems in healthcare.
In a related development, Cadence is set to participate in the Medicare ACCESS model, launching its first cohort in July 2024. This initiative aims to align payment structures with health outcomes rather than individual services, enabling technology-enabled care at reduced costs. Cadence is well-regarded for its remote patient monitoring programs, and CEO Chris Altchek has highlighted the role of AI in enhancing the company’s service offerings.
The landscape of telehealth is also shifting, as Hims announces a strategic retreat from marketing compounded versions of GLP-1 medications for obesity and diabetes. Instead, Hims will promote branded drugs from Novo Nordisk, which has recently withdrawn a patent infringement lawsuit against the telehealth provider. This change follows tensions that arose when Hims unveiled plans to market a compounded pill containing semaglutide, coinciding with Novo’s launch of its Wegovy product.
Amid discussions on AI’s impact on healthcare costs, Blue Cross Blue Shield has released an analysis suggesting that AI is indeed contributing to rising expenses. This analysis specifically examines claims related to postpartum hemorrhage, positing evidence of AI-driven coding practices.
In a significant corporate move, Talkspace is set to be acquired for $835 million by Universal Health Services. This acquisition marks a pivotal moment for Talkspace, which went public nearly five years ago amid a surge in demand for digital health services.
As discussions about health data governance evolve, a recent paper published in *Science* has proposed treating real-world health data as a public utility. Former chief data officer for ARPA-H, Alastair Thomson, argues that patients should have control over their data rather than the current holders, such as healthcare providers and electronic health record companies. This perspective aims to empower patients in the increasingly digitized healthcare landscape.
The ongoing developments in healthcare technology and policy underscore the industry’s dynamic nature, particularly as innovations continue to shape patient care and health management strategies.
